WHO BENEFITS FROM THE FDA’S VIGILANCE? — CERTAINLY NOT THE PATIENT! Newsletter Article 15 February 2013 Pages: 5 - 5
SPINAL SPASTICITY THERAPY REVOLUTIONISED BY BACLOFEN Newsletter Article 15 February 2013 Pages: 6 - 6
PLACE OF SODIUM CROMOGLYCATE IN LONG TERM ASTHMA THERAPY Newsletter Article 15 February 2013 Pages: 7 - 7
DIFTALONE HAS FASTER ONSET OF ANTI-INFLAMMATORY ACTIVITY Newsletter Article 15 February 2013 Pages: 8 - 8
RESULTS WITH BACLOFEN NOT AS GOOD AS PREVIOUS REPORTS Newsletter Article 15 February 2013 Pages: 9 - 9
A CASE OF FIBRINOUS PERITONITIS 18 MONTHS AFTER PRACTOLOL THERAPY Newsletter Article 15 February 2013 Pages: 11 - 11
STEROID THERAPY — HAZARDS INCREASED IN LIVER DISEASE Newsletter Article 15 February 2013 Pages: 11 - 11
PORPHYRIA CUTANEA TARDA PRECIPITATED BY OESTROGENS Newsletter Article 15 February 2013 Pages: 12 - 12
HYDRALAZINE METABOLITE MAY INDUCE ANTIBODY PRODUCTION Newsletter Article 15 February 2013 Pages: 13 - 13
NEW CEPHALOSPORINS ACTIVE AGAINST SERRATIA AND PSEUDOMONAS Newsletter Article 15 February 2013 Pages: 14 - 14
SALIVA LEVELS OF PHENYTOIN, CARBAMAZEPINE REFLECT FREE ANTICONVULSANT LEVELS Newsletter Article 15 February 2013 Pages: 15 - 15
PHARMACOKINETICS AND PHARMACODYNAMICS OF TOLAMOLOL Newsletter Article 15 February 2013 Pages: 16 - 16
DRUG BINDING TO BLOOD CELLS AND PLASMA PROTEINS — CHANGES DURING URAEMIA Newsletter Article 15 February 2013 Pages: 16 - 16
NALOXONE HAS ADVANTAGES OVER NALORPHINE AND LEVALLORPHAN Newsletter Article 15 February 2013 Pages: 17 - 17
MAO INHIBITORS OF CONSIDERABLE VALUE IN ATYPICAL DEPRESSION Newsletter Article 15 February 2013 Pages: 17 - 18
β-BLOCKERS NO SUBSTITUTE FOR CONVENTIONAL ANTITHYROID DRUGS Newsletter Article 15 February 2013 Pages: 18 - 18